Insider selling after a strong earnings beat is often routine, but the magnitude of CEO sales ($5M in two days) warrants monitoring for follow-on filings. If selling continues, it may signal limited near-term upside despite solid fundamentals.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 7 $107.91entry
- T+1 · 6mo ago +0.03%α −0.80% · $107.94
- T+5 · 6mo ago −9.03%α −10.53% · $98.17
- T+20 · 6mo ago −15.08%α −18.21% · $91.64
- T+60 · 4mo ago −3.98%α −7.82% · $103.61
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Three LeMaitre Vascular insiders, including CEO George LeMaitre, sold a total of $3.0M in open-market shares within a week of a strong Q1 earnings beat and raised guidance. CEO sales alone totaled $5.0M over two days, representing routine profit-taking after the stock's recent run-up.
Key Financial Metrics
Key Facts
- CEO George LeMaitre sold $2.0M on May 7 and $3.0M on May 8 at ~$107-109/share.
- Directors Lawrence Jasinski and Bridget Ross sold $434K and $560K respectively.
- Total open-market sales of $3.0M represent ~0.12% of LMAT's $2.5B market cap.
- Sales occurred 6 days after LMAT reported Q1 2026 EPS of $0.68 (+42% YoY) and raised full-year guidance.
Financial Impact
$3.0M in open-market insider sales, modest relative to $2.5B market cap
Risk Factors
- Further insider selling could pressure the stock.
- Stock may be fully valued after a strong run; multiple contraction risk.
- Earnings beat already priced in; guidance raise may be insufficient to sustain momentum.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-LMAT-1778538198155 |
Track record
14 reports on LMAT
2 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +12.26% at T+60 after the Feb 26, 2026 report. 2 of 4 went positive at some point.
Filters
- Nov 4, 202612d ago 8-K Bearish 6/10 Entry $83.49 to $77.65 Now $77.01 +7.76% ▲ +6.99% +10.29% vs SPY
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $80.60 to $79.02 Now $77.01 −4.45% ▼ −1.96% −1.37% vs SPY
- Oct 15, 20264w ago 8-K Neutral 2/10 Entry $80.82 to $84.45 Now $77.01 −4.71% ▲ +4.49% +4.40% vs SPY
- Aug 27, 202611w ago Press Release Neutral 2/10 Entry $80.45 to $80.67 Now $77.01 −4.28% ▲ +0.27% +0.16% vs SPY
- Jul 14, 202617w ago Press Release Neutral 1/10 Entry $99.79 Now $77.01 −22.83% No price data
- May 7, 202627w ago Insider Cluster Bearish 4/10 Viewing Entry $107.91 to $98.17 Now $77.01 +28.63% ▲ +9.03% +10.53% vs SPY
- May 7, 202627w ago Insider Cluster Neutral 2/10 Entry $107.91 to $98.17 Now $77.01 −28.63% ▼ −9.03% −10.53% vs SPY
- May 7, 202627w ago Insider Cluster Neutral 3/10 Entry $107.91 to $98.17 Now $77.01 −28.63% ▼ −9.03% −10.53% vs SPY
- May 5, 202627w ago 8-K Bullish 7/10 Entry $110.22 to $97.22 Now $77.01 −30.13% ▼ −11.79% −12.93% vs SPY
- Apr 14, 202630w ago DEFA14A Neutral 3/10 Entry $117.39 to $111.90 Now $77.01 −34.40% ▼ −4.68% −6.07% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers